DBV Technologies S.A. (DBVT) is a publicly traded Healthcare sector company. As of May 21, 2026, DBVT trades at $18.49 with a market cap of $1.11B and a P/E ratio of -17.67. DBVT moved +0.49% today. Year to date, DBVT is +9.12%; over the trailing twelve months it is +93.13%. Its 52-week range spans $2.20 to $26.19. Analyst consensus is buy with an average price target of $40.97. Rallies surfaces DBVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DBV Technologies Secures $229M Cash Runway to Q2 2027, Eyes BLA Filings: DBV Technologies held $229 million cash as of March 31, 2026, funding operations into Q2 2027 after exercise of ABSA and BS warrants. Net loss widened to $47.6 million in Q1 from $27.1 million, while loss per share improved to $0.11, reflecting financing strength and ramped R&D and commercial preparations.
| Metric | Value |
|---|---|
| Price | $18.49 |
| Market Cap | $1.11B |
| P/E Ratio | -17.67 |
| EPS | $-1.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.19 |
| 52-Week Low | $2.20 |
| Volume | 103.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.64M |
| Net Income | $-146.95M |
| Gross Margin | 0.00% |
6 analysts cover DBVT: 0 strong buy, 5 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $40.97.